The FDA has approved abemaciclib for use in combination with an aromatase inhibitor for the frontline treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.
Original Article: FDA Approves Frontline Abemaciclib for HR+/HER2- Advanced Breast Cancer